| Code | CSB-RA025141MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar based on the anti-TSLP antibody disclosed in CN 115210258 A, and it targets thymic stromal lymphopoietin (TSLP)—an epithelial cell–derived cytokine released at barrier tissues (e.g., airway/skin) in response to inflammatory stimuli. TSLP sits near the top of the type-2 inflammation cascade: by engaging its receptor complex (TSLPR with IL-7Rα) on immune cells, it helps initiate and amplify downstream mediators that shape allergic inflammation, including pathways upstream of IL-4/IL-5/IL-13 signaling.
By providing the antibody component as a non-therapeutic biosimilar reagent, this product supports mechanistic studies of TSLP neutralization, epithelial–immune crosstalk, and early inflammatory “trigger” biology without confounding factors from clinical formulation or combination regimens. It can be used as a benchmark antibody in discovery workflows (e.g., comparing blocking efficiency across candidate binders) or for rapid validation of TSLP-dependent phenotypes in in-vitro models. According to the product information, it is expressed in mammalian cells and positioned for research applications such as positive controls and functional verification of target biology.
There are currently no reviews for this product.